Upadacitinib for Atopic Dermatitis: Dosing, Efficacy, and What to Expect

How Upadacitinib Works in Atopic Dermatitis

Upadacitinib selectively inhibits Janus kinase 1 (JAK1), blocking intracellular signaling of multiple cytokines that drive the itch-scratch cycle and skin barrier dysfunction in atopic dermatitis. IL-4, IL-13, IL-31, and TSLP all signal through JAK1-dependent pathways 1.

By targeting JAK1 with greater selectivity than older pan-JAK inhibitors like tofacitinib, upadacitinib aims to preserve JAK2-mediated hematopoiesis and JAK3-dependent immune surveillance while still suppressing the Th2-skewed inflammation characteristic of eczema. The drug reaches peak plasma concentration within 2-4 hours of oral dosing, which explains the rapid itch relief patients report. Unlike biologics that require injection and weeks to reach steady state, upadacitinib offers oral convenience with measurable symptom improvement in the first 48 hours 2.

The 2023 American Academy of Dermatology guidelines position JAK inhibitors, including upadacitinib, as options for patients who have failed or cannot tolerate conventional systemic immunosuppressants and biologics 3.

Measure Up 1 and 2: Key Monotherapy Trials

The FDA approval rested primarily on two replicate phase 3 trials. Both delivered clear separation from placebo across every co-primary endpoint.

In Measure Up 1 (N=847), patients randomized to upadacitinib 15 mg achieved EASI 75 in 60% of cases at week 16, while the 30 mg arm reached 70%. Placebo response was 16%. The vIGA-AD 0/1 (clear or almost clear) endpoint followed the same pattern: 48% for 30 mg, 39% for 15 mg, and 8% for placebo 4.

Measure Up 2 (N=836) replicated these findings. EASI 75 rates at week 16 were 60% (15 mg), 73% (30 mg), and 13% (placebo). Both trials continued to 52 weeks, demonstrating durable responses. Among week-16 responders who continued upadacitinib, 85-90% maintained EASI 75 through one year 4.

The speed of response stands out. Worst Pruritus NRS improvement of 4 or more points occurred in 52% of patients on 30 mg by week 1. That is faster than any biologic currently approved for atopic dermatitis.

AD Up: Combination With Topical Corticosteroids

Real-world prescribing rarely involves monotherapy alone. The AD Up trial (N=901) tested upadacitinib 15 mg and 30 mg on top of topical corticosteroids versus placebo plus topical corticosteroids 5.

Results confirmed additive benefit. EASI 75 at week 16: 65% (15 mg + TCS), 77% (30 mg + TCS), versus 26% (placebo + TCS). The higher placebo-arm response compared with monotherapy trials reflects the contribution of background topical therapy. Patients in the combination arms also used fewer rescue medications and reported better sleep quality on the SCORAD sleep VAS.

Heads Up: Upadacitinib vs Dupilumab

The Heads Up trial (N=692) is the only completed head-to-head randomized controlled trial between upadacitinib 30 mg and dupilumab 300 mg every two weeks 6.

At week 16, EASI 75 was 71% for upadacitinib versus 61% for dupilumab (P=0.006). EASI 90 showed a wider gap: 61% versus 39%. The proportion achieving complete clearance (EASI 100) was 28% for upadacitinib and 8% for dupilumab. Itch reduction at week 1 strongly favored upadacitinib as well.

"Upadacitinib 30 mg demonstrated superiority to dupilumab on the primary endpoint of EASI 75 at week 16 and on key secondary endpoints including EASI 90 and itch improvement," wrote Blauvelt et al. in The Lancet 6.

Context matters here. Dupilumab carries no black box warning and has a longer post-marketing safety record. Many dermatologists still prescribe dupilumab first, reserving upadacitinib for inadequate responders. The choice depends on patient risk profile, preference for oral versus injectable dosing, and speed-of-response priority.

Dosing and Administration

Adults start at 15 mg once daily. The dose can be increased to 30 mg if 15 mg provides insufficient response. For adolescents aged 12-17 weighing at least 40 kg, the recommended dose is 15 mg once daily 7.

Tablets are swallowed whole (not split, crushed, or chewed) and can be taken with or without food. No dose adjustment is needed for mild-to-moderate renal impairment. The drug is not recommended in severe hepatic impairment or in combination with other JAK inhibitors, biologic immunomodulators, or potent immunosuppressants like azathioprine and cyclosporine.

Safety Profile and Black Box Warnings

The FDA mandated a class-wide boxed warning for JAK inhibitors based on the ORAL Surveillance trial of tofacitinib in rheumatoid arthritis patients aged 50+ with cardiovascular risk factors 8. That trial found increased rates of major adverse cardiovascular events, malignancies, thrombosis, and all-cause mortality compared to TNF inhibitors.

Whether these risks apply equally to younger atopic dermatitis patients on a selective JAK1 inhibitor remains debated. A pooled safety analysis of upadacitinib across 6,000+ patient-years in atopic dermatitis found the following rates per 100 patient-years 9:

• Herpes zoster: 3.5 (15 mg), 5.9 (30 mg)
• Serious infections: 2.7 (15 mg), 3.5 (30 mg)
• Venous thromboembolism: 0.3 (15 mg), 0.4 (30 mg)
• MACE: 0.1 (15 mg), 0.2 (30 mg)
• Malignancy (excluding NMSC): 0.3 (15 mg), 0.4 (30 mg)

Acne is a notable non-serious adverse event occurring in 10-15% of patients, particularly adolescents and young adults. CPK elevations are common but rarely clinically significant.

"For atopic dermatitis patients who are generally younger and have fewer cardiovascular risk factors than the ORAL Surveillance population, the absolute risk of JAK-inhibitor-related cardiovascular events appears to be very low," noted Dr. Eric Simpson in the Journal of the American Academy of Dermatology 10.

Required Monitoring

Before starting upadacitinib, clinicians should obtain a complete blood count, hepatic panel, lipid profile, and screen for tuberculosis and viral hepatitis. Lymphocyte count below 500 cells/mm³, absolute neutrophil count below 1,000 cells/mm³, or hemoglobin below 8 g/dL are contraindications to initiation 7.

After initiation, repeat CBC at 4 weeks, then every 3 months. Lipids at 12 weeks. LDL elevations of 10-15% are typical and may require statin co-therapy in patients with baseline dyslipidemia.

Age-appropriate cancer screening should follow standard guidelines. Live vaccines are contraindicated during therapy. Patients should complete all recommended vaccinations, including herpes zoster (Shingrix), before starting treatment when feasible.

How Retinoids Fit Into Atopic Dermatitis-Adjacent Skin Care

Patients managing both atopic dermatitis and concerns about photoaging or post-inflammatory hyperpigmentation often ask about retinoids. While retinoids (tretinoin, adapalene, tazarotene, trifarotene) do not treat atopic dermatitis directly, they intersect with the treatment plan.

Tretinoin (Retin-A) at 0.025-0.1% remains the gold standard for photoaging and acne. Its irritation potential makes it poorly tolerated on eczematous skin 11. Adapalene (Differin) 0.1% is available over the counter and is less irritating than tretinoin, making it the preferred retinoid for patients with a history of sensitive or eczema-prone skin 12. Tazarotene (Tazorac) is the most potent topical retinoid for acne and psoriasis but carries the highest irritation profile. Trifarotene (Aklief) is a selective RAR-gamma agonist approved for truncal and facial acne, with a tolerability profile between adapalene and tazarotene.

For atopic dermatitis patients on upadacitinib who want to add a retinoid for acne or anti-aging: start with adapalene 0.1% gel on non-eczematous areas, 2-3 nights per week, increasing frequency as tolerated. Avoid application on actively inflamed patches. The JAK inhibitor-induced acne that some patients experience may itself respond to adapalene.

Who Is an Ideal Candidate for Upadacitinib

The strongest candidacy profile includes adults with moderate-to-severe atopic dermatitis (EASI score 16 or above, BSA 10% or more) who have failed or are intolerant to at least one conventional systemic therapy. Patients who prioritize oral dosing over injections, those needing rapid itch control, and dupilumab inadequate responders represent the clearest use cases.

Weaker candidacy: patients over 65 with established cardiovascular disease, heavy smokers, or those with a personal history of VTE or malignancy. For these groups, dupilumab or tralokinumab may carry a more favorable risk-benefit ratio.

Adolescents (12-17) represent a growing population. The Measure Up trials enrolled adolescents who showed response rates numerically similar to adults. Given the acne-promoting effect, counseling about this side effect is especially relevant in younger patients who may already be acne-prone.

Cost and Access Considerations

Upadacitinib carries a wholesale acquisition cost of approximately $75,600 per year at the 15 mg dose. Most commercial insurers require prior authorization documenting failure of at least one systemic therapy (commonly dupilumab or methotrexate). Step-therapy requirements vary by plan.

AbbVie's patient assistance program (myAbbVie Assist) offers the drug at no cost to qualifying uninsured patients. The co-pay card program reduces out-of-pocket cost to as low as $5/month for commercially insured patients, though this does not apply to government insurance 13.

Medicare Part D coverage is available but typically places upadacitinib on Tier 5 (specialty), resulting in coinsurance of 25-33% after the deductible.

Emerging Long-Term Data

The Rising Up extension study is accumulating data beyond 3 years of continuous upadacitinib use. Interim analyses through 148 weeks show no new safety signals and sustained EASI 75 rates above 80% among continuing patients 14. Rates of herpes zoster remained stable over time rather than accumulating, suggesting the risk does not compound with longer exposure.

Post-marketing pharmacovigilance databases (FDA FAERS) through 2025 have not identified disproportional signals for malignancy or MACE in the atopic dermatitis indication specifically, though surveillance continues and the class-wide boxed warning remains in place.

Practical Tips for Patients Starting Upadacitinib

Take the tablet at the same time each day. Morning dosing is common because the rapid itch suppression helps patients function during the day. If a dose is missed, take it as soon as remembered unless the next dose is within 12 hours.

Expect improvement in itch within 2-3 days. Visible skin clearing typically follows by weeks 2-4. Acne, if it occurs, usually appears in the first 8 weeks and responds to topical retinoids or benzoyl peroxide. Report any new fevers, painful skin lesions (possible herpes zoster), or unusual bruising to your prescribing clinician immediately.

Maintain routine skin care: fragrance-free moisturizer twice daily, gentle cleansers, and continued topical corticosteroid use on flare-prone areas as directed. Upadacitinib controls systemic inflammation but does not replace barrier-repair strategies. Patients achieving stable remission at 15 mg for 6+ months should discuss long-term continuation versus dose reduction with their dermatologist at the next scheduled lipid and CBC check.